Literature DB >> 33741864

Prediction of tumor response and patient outcome after radioembolization of hepatocellular carcinoma using 90Y-PET-computed tomography dosimetry.

Philippe d'Abadie1, Stephan Walrand1, Michel Hesse1, Laurence Annet2, Ivan Borbath3, Marc Van den Eynde3, Renaud Lhommel1, François Jamar1.   

Abstract

AIM: 90Y-radioembolization using glass or resin microspheres is increasingly used for the treatment of hepatocellular carcinoma (HCC). The aim of this retrospective study is to determine the prognostic relevance of dosimetric parameters defined with 90Y-PET-CT obtained immediately after radioembolization.
METHODS: Forty-five HCC patients, mostly with multiple lesions, were treated by radioembolization between 2011 and 2017. After treatment, all underwent a 90Y PET-CT with time of flight reconstruction (90Y-TOF-PET-CT). Tumor absorbed dose and cumulative tumor dose-volume histogram were calculated using a dose point Kernel convolution algorithm. The radiological tumor response was assessed using modified (m)-RECIST criteria. Progression-free-survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox regression analysis.
RESULTS: Twenty-six patients were treated with glass microspheres (73 lesions) and nineteen with resin microspheres (60 lesions). Thresholds of 118 and 61 Gy for glass and resin microspheres respectively correlate well with radiological response with a positive predictive value (PPV) of 98 and 80% and discriminate patient outcome with regard to PFS (P = 0.03 and 0.005) and OS (P = 0.003 and 0.007). Using dose volume histogram, a minimal absorbed dose of 40 Gy in 66% of the tumor volume (defined as D66) was highly predictive of radiological response (PPV = 94%), PFS (P < 0.001) and OS (P = 0. 008), for either device.
CONCLUSION: Dosimetric parameters obtained using 90Y-PET-CT are predictive of tumor response, PFS and OS. In clinical practice, a systematic dosimetric evaluation using 90Y PET should be implemented to help predicting patient outcomes.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33741864     DOI: 10.1097/MNM.0000000000001395

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  5 in total

1.  Pre- and post-treatment image-based dosimetry in90Y-microsphere radioembolization using the TOPAS Monte Carlo toolkit.

Authors:  Alejandro Bertolet; Eric Wehrenberg-Klee; Mislav Bobić; Clemens Grassberger; Joseph Perl; Harald Paganetti; Jan Schuemann
Journal:  Phys Med Biol       Date:  2021-12-29       Impact factor: 3.609

Review 2.  Trans-arterial Radioembolization Dosimetry in 2022.

Authors:  Etienne Garin; Boris Guiu; Julien Edeline; Yan Rolland; Xavier Palard
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-18       Impact factor: 2.797

3.  Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Carlo Chiesa; Paul Haste; Bruno Sangro; Beau Toskich; Kirk Fowers; Joseph M Herman; S Cheenu Kappadath; Thomas Leung; Daniel Y Sze; Edward Kim; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-17       Impact factor: 10.057

Review 4.  Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria.

Authors:  Philippe d'Abadie; Stephan Walrand; Renaud Lhommel; Michel Hesse; Ivan Borbath; François Jamar
Journal:  Curr Oncol       Date:  2022-03-29       Impact factor: 3.109

Review 5.  Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects.

Authors:  Philippe d'Abadie; Michel Hesse; Amandine Louppe; Renaud Lhommel; Stephan Walrand; Francois Jamar
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.